Correction to “Metformin vs Myoinositol: Which Is Better in Obese Polycystic Ovary Syndrome Patients? A Randomized Controlled Crossover Study”

Tagliaferri, V., Romualdi, D., Immediata, V., De Cicco, S., Di Florio, C., Lanzone, A. and Guido, M. (2017), Metformin vs Myoinositol: Which Is Better in Obese Polycystic Ovary Syndrome Patients? A Randomized Controlled Crossover Study. Clin Endocrinol, 86: 725–730. https://doi.org/10.1111/cen.13304 In Table 1: 1 Table Clinical and hormonal features at baseline and after 6 months of MYO and metformin treatment. (Table presented.) Data are expressed as medians with their respective interquartile range (IQR). Abbreviations: A, androstenedione; AMH, anti-müllerian hormone; BMI, body mass index; FAI, free androgen index; F-G, Ferriman-Gallwey; MYO, myoinositol PRL, prolactin; SHBG, sex hormone-binding globulin; WHR, waist to hip ratio; 17 OHP, 17 hydroxyprogesterone. *p < 0.05. The value “29.7 (IQR 7.8)” in the “BMI (kg/m2)” row under the “Baseline (IQR)” of “Metformin” was incorrect and should be “32.5 (IQR 7.9)”. The value “32.5 (IQR 7.9)” in the “BMI (kg/m2)” row under the “After 6 months (IQR)” of “Metformin” was incorrect and should be “29.7 (IQR 7.8)”. The value “10.52 (37.78)” in the “Ovarian Volume (cm3)” row under the “After 6 months (IQR)” of “MYO” was incorrect and should be “10.52 (3.78)”. The value “02.3 (1.1)” in the “17(OH)P (nmol/l)” row under the “After 6 months (IQR)” of “MYO” was incorrect and should be “2.3 (1.1)”. The correct Table 1 is provided below. We apologize for this error.